Dergiler / Veterinary Journal of Mehmet Akif Ersoy University / 2021 / Cilt: 6 Sayı: 3

Investigation of the Effect of Linoleic Acid on Vascularization in Experimentally Induce Zoledronic Acid-Related Osteonecrosis in Rats

Sayfa
122–126
Yayın Tarihi
2021-12-31
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

However, no definite conclusion could be reached about the neovascularization efficiency of CLA within the period evaluated after tooth extraction.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is an increasingly common pathological condition whose pathophysiology is not fully understood and can be difficult to manage.
📊
Temel Bulgular & Veri:A total of 50 Wistar Albino male rats weighing 400-450 grams were used.
💡
Sonuç & Katkı:However, no definite conclusion could be reached about the neovascularization efficiency of CLA within the period evaluated after tooth extraction.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Bisphosphonate · Conjugated linoleic acid · Osteonecrosis

Abstract

Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is an increasingly common pathological condition whose pathophysiology is not fully understood and can be difficult to manage. The unique biological effects of conjugated linoleic acid (CLA) include angiogenic, anticarcinogenic, antiatherosclerotic, antioxidative, immunomodulative and antibacterial effects. The aim of this study is to compare the osteonecrosis areas created by tooth extraction with the control group using scanning electron microscopy (SEM) after the administration of zoledronic acid (ZA), CLA and a combination of both in the rat jaw. A total of 50 Wistar Albino male rats weighing 400-450 grams were used. The groups were randomly divided into 5 groups: the control group, the sham group, the group that received ZA, the groups that received CLA with ZA (100 mg / kg and 200 mg / kg), and the study lasted a total of 10 weeks. Regardless of the use of ZA, it was observed by SEM that vascularization was impaired in all groups with tooth extraction. Neovascularization did not occur in the groups where CLA was applied, regardless of the dose. It was concluded that SEM analysis and corrosion casts technique can be considered as an alternative method in such studies due to its accessibility and low cost in observing dental vascularization. However, no definite conclusion could be reached about the neovascularization efficiency of CLA within the period evaluated after tooth extraction.

🔖

Bu Makaleye Atıf Yap

YURTAL, Z., SERİNDERE, G., BELGİN, C. A., TAKCI, L. (2021). Investigation of the Effect of Linoleic Acid on Vascularization in Experimentally Induce Zoledronic Acid-Related Osteonecrosis in Rats. Veterinary Journal of Mehmet Akif Ersoy University, Cilt: 6 Sayı: 3, 122–126. https://ajindex.com/articles/931197

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest. 1996;97:2692-6
  2. Lewiecki EM. Safety of long-term bisphosphonate therapy for the management of osteoporosis. Drugs. 2011;71:791-814
  3. Harrington JT, Ste-Marie LG, Brandi ML, Civitelli R, Fardellone P, Grauer A, et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int. 2004;74:129–35
  4. Pols HA, Felsenberg D, Hanley DA, Stepán J, Muñoz-Torres M, Wilkin TJ, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int. 1999;9(5):461-8
  5. Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol. 2009;27(32):5356-62
  6. Walter C, Al-Nawas B, Frickhofen N, GammH, Beck J, Reinsch L, et al. Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients. Head Face Med. 2010;6:11
  7. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753–61
  8. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B; Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. Aust Endod J. 2009;35(3):119-30
  9. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007;65:2397–410
  10. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63:1567–75
  11. Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol. 2008;44:857–69
  12. Pabst A, Ziebart T, Ackermann M, Konerding M, Walter C. Bisphosphonates’ Antiangiogenic Potency in the Development of B